As­traZeneca inks $247M deal with gen­er­a­tive AI shop Ab­sci to de­vel­op an­ti­body drug for can­cer

Last year
Deals
AI

FDA ap­proves Lil­ly’s BTK in­hibitor Jaypir­ca for two more blood can­cers

Last year
Pharma
FDA+

Up­dat­ed: Roche buys obe­si­ty and di­a­betes biotech Car­mot Ther­a­peu­tics in $2.7B merg­er deal

Last year
Deals

FDA’s CAR-T safe­ty probe; Ab­b­Vie’s $10B ADC wa­ger; Pfiz­er’s GLP-1 set­back; Ace­lyrin’s CRO dra­ma; and more

Last year
Weekly

Sam­sung Bioepis strikes deal for Ste­lara biosim­i­lar, but launch like­ly won't come in time for an IRA ex­emp­tion

Last year
Pharma
FDA+

Apel­lis' eye dis­ease drug gets safe­ty la­bel up­date for rare in­flam­ma­tion side ef­fect

Last year
R&D
FDA+

Pfiz­er, Idor­sia and Ab­b­Vie drug brands lead the way in phar­ma dig­i­tal mar­ket­ing — study

Last year
Marketing

EMA sends more ques­tions to GLP-1 mak­ers over pos­si­ble risk of sui­cide, self-harm

Last year
Pharma

No­var­tis taps ‘So­pra­nos’ ac­tress for new mul­ti­ple scle­ro­sis Kes­imp­ta cam­paign

Last year
Pharma
Marketing

Ot­su­ka am­pli­fies re­search-based men­tal health pro­gram, adds first dig­i­tal ac­cess

Last year
Pharma
Marketing

Ex­clu­sive: San Diego biotech rais­es $11.7M to use cells as tar­get­ed de­liv­ery ves­sels for ge­net­ic med­i­cines

Last year
Financing
Startups

Tharim­mune's pub­lic of­fer­ing; Cul­mi­na­tion Bio rais­es $10M; Pep­per Bio's seed round led by NFX

Last year
News Briefing

ARCH-al­lied AN Ven­ture Part­ners rais­es $200M to build biotechs out of re­search from Japan

Last year
Financing
Startups

Af­ter tar­get­ing strug­gling biotechs, Tang’s Con­cen­tra shifts gears with un­so­licit­ed bid for Lian­Bio

Last year
Deals

Amy­lyx hires new CMO from Ul­tragenyx; Eliot Forster is back as a CEO af­ter F-star sale

Last year
Peer Review

Up­dat­ed: Pfiz­er aban­dons twice-dai­ly GLP-1 ap­proach due to high dis­con­tin­u­a­tion rates, goes back to PhI with ...

Last year
R&D

Al­tim­mune’s fate turns around af­ter longer look at obe­si­ty tri­al

Last year
R&D

As­traZeneca halts two PhI­II hy­per­kalemia stud­ies in­tend­ed to spot­light Lokel­ma’s clin­i­cal val­ue

Last year
Pharma

Small transpa­cif­ic team led by Lil­ly, Ever­est vet turns to com­pu­ta­tion­al tools for next wave of pep­tide drug ...

Last year
Financing
Startups

J&J ac­quires Cal­i­for­nia med­ical de­vice com­pa­ny for $400M

Last year
Deals
Pharma

More com­pa­nies need to set di­ver­si­ty en­roll­ment goals in can­cer tri­als, FDA says

Last year
FDA+

Drug prices in TV ads again? Sen­a­tors take an­oth­er swing with ex­pe­dit­ed bill

Last year
Pharma
Marketing

No­vo Nordisk ramps up le­gal case against com­pound­ing phar­ma­cies sell­ing 'mis­brand­ed' semaglu­tide

Last year
Pharma
Law

FDA ships Form 483 to gener­ic drug gi­ant Dr. Red­dy’s due to equip­ment is­sues, oth­er ob­ser­va­tions

Last year
Pharma
FDA+
First page Previous page 237238239240241242243 Next page Last page
A service from the Financial Times